Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP-CD/LD in fluctuating Parkinson's disease
NCT00947037Phase 2Withdrawn
- Sponsor
- Intec Pharma Ltd.
- Start
- Aug 2012
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carbidopa + levodopa in Parkinson's disease (PD), sponsored by Intec Pharma Ltd. Primary endpoints: Clinical Global Impression and Global Satisfaction Score. Planned start Aug 2012; status: withdrawn.
02
Drugs
carbidopa + levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00947037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00947037.